Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0824 Kronos
BioCentury & Getty Images

Finance

$155M Perceptive-led note deal enables Kronos to fund newly acquired Gilead asset’s pivotal trial

Aug 25, 2020 | 12:48 AM GMT

After acquiring a Phase III-ready asset from Gilead last month, Kronos raised $155 million on Monday to

Read the full 431 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE